- Investing Ideas
- /
- U.S. Potentially Undervalued Companies
U.S. Potentially Undervalued Companies
Results
6292
0 new
Companies with a Value score of at least 3, ordered by Value score
6,292 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
SAMG | US$17.19 | 4.2% | 8.3% | US$236.0m | US$23.50 | PE19.4x | E21.2% | 4.7% | Diversified Financials | ||
ATHE | AU$1.33 | 7.7% | -46.6% | AU$21.3m | AU$11.93 | PS5.7x | E-2.7% | n/a | Pharmaceuticals & Biotech | ||
SMBC | US$54.60 | -1.7% | 41.1% | US$615.2m | US$60.00 | PB1.3x | E10.8% | 1.7% | Banks | ||
BKRK.Y | Rp16.89 | -3.6% | -0.2% | Rp768.9t | Rp19.56 | PB2.5x | E9.4% | 6.3% | Banks | ||
MEDI.F | CA$0.05 | 0.5% | -6.2% | CA$26.7m | n/a | PB0.6x | S28.8% | n/a | Pharmaceuticals & Biotech | ||
CNTB | US$1.35 | 9.8% | 64.8% | US$77.9m | US$7.00 | PS3.1x | E-15.9% | n/a | Pharmaceuticals & Biotech | ||
MTB | US$175.42 | -2.3% | 38.7% | US$29.3b | US$184.56 | PB1.1x | E5.4% | 3.1% | Banks | ||
ACNB | US$43.18 | -0.7% | 36.6% | US$357.4m | US$41.00 | PB1.3x | E-9.1% | 3.0% | Banks | ||
ENFN | US$9.47 | 5.5% | 5.6% | US$1.2b | US$9.36 | PE280.7x | E66.6% | n/a | Software | ||
OVLY | US$27.15 | -1.3% | 8.3% | US$219.9m | n/a | PB1.3x | n/a | 1.7% | Banks | ||
DSGR | US$38.09 | 1.4% | 46.5% | US$1.8b | US$41.00 | PS1x | E90.8% | n/a | Capital Goods | ||
LFLY | US$2.18 | -6.0% | -66.0% | US$5.4m | US$7.59 | PE-0.9x | S-9.1% | n/a | Media | ||
WEIG.F | UK£29.66 | 5.6% | 28.8% | UK£5.7b | UK£30.97 | PE25.7x | E19.5% | 1.8% | Capital Goods | ||
ZFSV.F | CHF 599.04 | 0.7% | 30.2% | CHF 73.8b | CHF 568.08 | PE18x | E7.9% | 4.6% | Insurance | ||
IOVA | US$9.61 | -5.3% | 111.2% | US$2.8b | US$24.42 | PS89x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
RFIL | US$3.74 | 0.8% | 24.3% | US$38.3m | US$4.50 | PB1.1x | E99.2% | 0% | Tech | ||
MRX | US$23.58 | 1.0% | n/a | US$1.7b | US$29.50 | PE10.5x | E16.6% | 2.4% | Diversified Financials | ||
NKTR | US$1.17 | -10.0% | 96.4% | US$204.3m | US$1.30 | PS2.3x | E4.7% | n/a | Pharmaceuticals & Biotech | ||
OTLY | US$1.01 | 11.1% | 12.7% | US$608.9m | US$1.97 | PB2.5x | E48.4% | n/a | Food, Beverage & Tobacco | ||
HMSN.F | UK£0.32 | -8.0% | 10.9% | UK£1.6b | n/a | PB0.8x | E59.8% | 4.9% | Real Estate | ||
MESO | AU$7.60 | 10.9% | 208.9% | AU$1.3b | AU$9.86 | PS150.2x | E60.8% | n/a | Pharmaceuticals & Biotech | ||
OLP | US$27.45 | -1.7% | 45.5% | US$576.4m | US$26.75 | PB1.9x | E-34.2% | 6.6% | Real Estate | ||
RZLT | US$4.98 | -2.0% | 277.3% | US$270.1m | US$12.33 | PB3.9x | E48.6% | n/a | Pharmaceuticals & Biotech | ||
VCEL | US$43.19 | -7.3% | 28.8% | US$2.2b | US$57.14 | PE2683.9x | E51.6% | n/a | Pharmaceuticals & Biotech |